A. Salud Salvia

Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept

A. Fernández Montes, E. Aranda Aguilar, P. García-Alfonso, 2021, Clinical and Translational Oncology.

Patient and tumor characteristics as determinants of overall survival (OS) in BRAF V600 mutant (mt) metastatic colorectal cancer (mCRC) treated with doublet or triplet targeted therapy.

J. Tabernero, R. Dienstmann, I. Chicote, 2020 .

Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer

A. Salud Salvia, A. Gasol Cudós, S. Morales Murillo, 2021, Breast.